Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

PHASE3RecruitingINTERVENTIONAL
Enrollment

266

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Tislelizumab combined with GX

"Tislelizumab:200mg vgtt,q3w;treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine:1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles. Capecitabine: 1000mg/m2, bid,po, d1-14, q3; treatment until disease progression, patients withdrawal of informed, or intolerable toxicity."

DRUG

Tislelizumab combined with GP

"Tislelizumab: 200mg vgtt,q3w;treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine: 1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles; Cisplatin: 80mg/m2, ivgtt, d1 (high-dose cisplatin antiemetic and hydration regimen), q3w,repeat 4 \~ 6 cycles."

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER